18 Top Takeaways Lp(a) is largely determined by genetics. Lp(a) is elevated in approximately 20% of the general population. Elevated Lp(a) is overrepresented in the Black community. Lp(a) elevation is known to drive atherosclerosis and intravascular inflammation, increasing the risk for ASCVD and PAD. Patients with elevated Lp(a) have worse outcomes related to PAD and high incidence of MALE. Patients with PAD are candidates for screening for Lp(a) elevation. Lipoprotein Apheresis is currently the sole FDA-approved treatment for lowering Lp(a), only in individuals with clinically diagnosed Familial Hypercholesterolemia with documented coronary or peripheral artery disease and LDL-C levels greater than 100 mg/dL.36 Therapies to reduce Lp(a) levels are in development. 1 2 3 4 5 6 7
RkJQdWJsaXNoZXIy MjI2NjI=